The Pandemic As A Catalyst For Drug Development
Source: Life Science Leader
Rob Wright, chief editor of Life Science Leader, conducted a virtual roundtable with four CEOs of publicly traded biopharmaceutical companies (view full video here). In this segment, Ted Love, M.D., CEO of Global Blood Therapeutics (NASDAQ: GBT), Jeremy Levin, D.Phil., MB BChir, CEO, Ovid Therapeutics (NASDAQ: OVID), and Rachel King, CEO of GlycoMimetics, (NASDAQ: GLYC), talk about how the pandemic has catalyzed drug development.
This website uses cookies to ensure you get the best experience on our website. Learn more